Arzerra Plus Chlorambucil Gets FDA Nod

Share this content:
A "Game Changer" in ALL and CLL?
A "Game Changer" in ALL and CLL?

The FDA has approved a new indication for Arzerra (ofatumumab; GlaxoSmithKline) to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

The approval is based on a multi-center, randomized, open-label trial of comparing ofatumumab in combination with chlorambucil to single agent chlorambucil. The trial enrolled 447 patients with CLL and for whom fludarabine-based therapy was not appropriate due to advanced age or presence of co-morbidities. Patients received pre-medication with acetaminophen, an antihistamine, and a glucocorticoid prior to the ofatumumab infusion.

RELATED: Hematologic Cancers Resource Center

The trial met the primary endpoint of progression free survival (PFS), with a median PFS of 22.4 months (95% CI: 19.0, 25.2 months) for patients receiving Arzerra in combination with chlorambucil, compared to 13.1 months (95% CI: 10.6, 13.8 months) for patients receiving chlorambucil [hazard ratio 0.57 (95% CI: 0.45, 0.72), stratified log-rank P-value <0.001].

Arzerra, a CD20-directed cytolytic monoclonal antibody, is already approved for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Arzerra is available as 100mg/5mL and 1000mg/50mL strengths in single-use vials.

For more information call (888) 825-5249 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs